Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Pain research using electronic diaries helps identify who responds to ’placebo effect’


Study among people with fibromyalgia suggests those with greater swings in pain hour-to-hour, day-to-day are more likely to respond to placebos

Studies involving people who suffer from chronic pain often give some of them placebos, "sugar pills" with no medicinal value, to show whether the treatment has real value. Little is known, however, about the types of people who tend to respond positively to placebos, a mystery that places a hurdle before researchers who want to learn the best way to treat people’s pain.

A new study by researchers at the University of Michigan Health System sheds some light on one group of people that seems to experience the "placebo effect." The researchers found that people with one type of chronic pain who have greater swings in their pain fluctuations tend to be more likely to respond to placebos.

The study of people with fibromyalgia – a type of chronic pain affecting several million people that typically involves tenderness, stiffness and fatigue – appears in the current edition of the journal Arthritis & Rheumatism.

"There is substantial evidence that the placebo effect has strong biological underpinnings, and that some individuals are more likely than others to demonstrate this effect," says Daniel J. Clauw, M.D., director of the U-M Chronic Pain and Fatigue Research Center and professor of rheumatology at the U-M Medical School.

"This study suggests that individuals with greater hour-to-hour and day-to-day variability in their pain may be more likely to be placebo responders," says Clauw, senior author of the paper. "When such individuals are placed in clinical trials of new interventions, the strong placebo effect they experience can make it difficult to determine if there is a superimposed effect of the treatment being tested."

"This finding is important because so far, nobody has been able to fingerprint placebo responders," adds Richard A. Harris, Ph.D., lead author of the paper, research investigator in the Division of Rheumatology at the U-M Medical School’s Department of Internal Medicine and a researcher at the Chronic Pain and Fatigue Research Center. "The research is helping us gain a better understanding of who responds to placebos. That’s especially important to the research community as we design clinical trials."

It is not clear if these findings are only present in fibromyalgia, or may also be seen in other chronic pain conditions, the researchers said.

Each of the 125 participants in the study carried a Palm-based electronic diary and was prompted at random intervals to record his or her pain level. Participants were prompted on average about three and a half times per day.

The patients who were enrolled in a multicenter drug trial of the anti-depressant milnacipran versus a placebo. Some of the participants experienced a large range of pain variability, while others experienced pain at fairly constant levels.

Those whose pain levels varied widely were more likely to respond to the placebo. They were not, the researchers found, necessarily more likely to respond to milnacipran, which suggests that high pain variability may be a predictor of a placebo response.

"These results have direct implications for drug trials in fibromyalgia and perhaps broader implications for other pain syndromes," the researchers note.

The researchers also found that the electronic recording of pain levels was much more accurate than earlier pencil-and-paper recordings. The electronic system contained a time stamp when the participants recorded the data, removing some of the uncertainty and inaccuracy that often accompanied pencil-and-paper diaries.

Fibromyalgia is a common condition that affects 2 to 4 percent of the U.S. population and is more commonly diagnosed in women. Clauw and his colleagues at the Chronic Pain and Fatigue Research Center are conducting extensive research into the causes and treatments of fibromyalgia.

For more about the U-M Chronic Pain and Fatigue Research Center, go to For more about other recent research at U-M related to pain and the placebo effect, go to

In addition to Clauw and Harris, other authors of the study were David A. Williams, Ph.D., associate professor of psychiatry at the U-M Medical School, director of research development within the Center for the Advancement of Clinical Research at U-M and co-director of the Chronic Pain and Fatigue Research Center; Samuel A. McLean, M.D., lecturer in the Department of Emergency Medicine at the U-M Medical School; Ananda Sen, Ph.D., associate research scientist at the U-M Center for Statistical Consultation and Research; Richard H. Gracely, Ph.D., professor of internal medicine and neurology at the U-M Medical School and co-director of the Chronic Pain and Fatigue Research Center; Michael Hufford, Ph.D., of Amylin Pharmaceuticals, San Diego, Calif.; and R. Michael Gendreau, M.D., of Cypress Bioscience, San Diego, Calif.

Katie Gazella | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

nachricht New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>